GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (NAS:ILMN) » Definitions » Altman Z-Score

Illumina (Illumina) Altman Z-Score

: 2.80 (As of Today)
View and export this data going back to 2000. Start your Free Trial

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 2.78 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

Illumina has a Altman Z-Score of 2.80, indicating it is in Grey Zones. This implies that Illumina is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Illumina's Altman Z-Score or its related term are showing as below:

ILMN' s Altman Z-Score Range Over the Past 10 Years
Min: 2.78   Med: 10.09   Max: 13.42
Current: 2.78

During the past 13 years, Illumina's highest Altman Z-Score was 13.42. The lowest was 2.78. And the median was 10.09.


Illumina Altman Z-Score Historical Data

The historical data trend for Illumina's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.24 13.42 9.14 2.81 3.27

Illumina Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.81 3.65 2.88 3.34 3.27

Competitive Comparison

For the Diagnostics & Research subindustry, Illumina's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Illumina Altman Z-Score Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Illumina's Altman Z-Score falls into.



Illumina Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Illumina's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.1028+1.4*-0.0019+3.3*-0.1029+0.6*4.2834+1.0*0.4455
=2.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $10,111 Mil.
Total Current Assets was $2,609 Mil.
Total Current Liabilities was $1,570 Mil.
Retained Earnings was $-19 Mil.
Pre-Tax Income was -167 + -782 + -89 + -78 = $-1,116 Mil.
Interest Expense was -18 + -19 + -19 + -20 = $-76 Mil.
Revenue was 1122 + 1119 + 1176 + 1087 = $4,504 Mil.
Market Cap (Today) was $18,701 Mil.
Total Liabilities was $4,366 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(2609 - 1570)/10111
=0.1028

X2=Retained Earnings/Total Assets
=-19/10111
=-0.0019

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-1116 - -76)/10111
=-0.1029

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=18701.357/4366
=4.2834

X5=Revenue/Total Assets
=4504/10111
=0.4455

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Illumina has a Altman Z-Score of 2.80 indicating it is in Grey Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Illumina  (NAS:ILMN) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Illumina Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Illumina's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Illumina (Illumina) Business Description

Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Executives
Aimee L Hoyt officer: SVP, Chief People Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jacob Thaysen director, officer: Chief Executive Officer 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Susan H Tousi officer: SVP Product Development 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Steven Barnard officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott B. Ullem director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Stephen P Macmillan director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Andrew Teno director C/O FIR TREE INC., 55 WEST 46TH STREET, 29TH FLOOR, NEW YORK NY 10036
Alexander Aravanis officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott D Ericksen officer: VP, Chief Accounting Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Charles Dadswell officer: Sr VP & General Counsel 5200 ILLUMINA WAY, SAN DIEGO CA 92122
John Edward Frank officer: Chief Public Affairs Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Phillip G. Febbo officer: SVP Chief Medical Officer C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carissa Rollins officer: SVP, Chief Information Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Kevin Carl Pegels officer: Chief of Global Operations 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jay T Flatley officer: President & CEO 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121

Illumina (Illumina) Headlines

From GuruFocus

Illumina Inc 2022 Investor Day Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Illumina Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Illumina Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024

Illumina Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024